tocilizumab + saline solution
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hand Osteoarthritis
Conditions
Hand Osteoarthritis
Trial Timeline
Nov 20, 2015 → Feb 1, 2019
NCT ID
NCT02477059About tocilizumab + saline solution
tocilizumab + saline solution is a phase 3 stage product being developed by Roche for Hand Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02477059. Target conditions include Hand Osteoarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02477059 | Phase 3 | Completed |
Competing Products
17 competing products in Hand Osteoarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lebrikizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Methylprednisolone Tablet | Johnson & Johnson | Phase 2/3 | 65 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Pimecrolimus Cream 1% | Novartis | Phase 3 | 77 |
| denosumab + Placebo | Amgen | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |
| dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| clobetasol propionate | GSK plc | Approved | 84 |
| urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream) | Bayer | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 2 | 49 |
| Ruxolitinib | Incyte | Phase 1/2 | 38 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream | Arcutis Biotherapeutics | Phase 1/2 | 36 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |